Core Insights - Calidi Biotherapeutics, Inc. has successfully executed its 2025 priorities and is set to file an IND application for its lead candidate CLD-401 by the end of 2026 [2][4][9] 2025 Accomplishments - The company demonstrated the effectiveness of its RedTail platform in preventing immune clearance and specifically targeting tumor cells, achieving comparable genetic medicine expression levels to localized dosing while avoiding systemic exposure [2][5] - CLD-401, the first lead candidate, is designed to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease [4][9] - New preclinical data presented at ASCO and SITC showed enhanced biological efficacy of CLD-401 in immunocompetent tumor models, confirming its ability to replicate in tumor cells and avoid immune clearance [5][6] - The management team was strengthened with the appointment of Eric Poma, PhD, as CEO and Guy Travis Clifton, MD, as CMO, both bringing extensive biopharmaceutical experience [5][8] Financial Performance - Calidi reduced its term debt and notes payable by $3.1 million in 2025, decreasing from $3.8 million at the end of 2024 to $0.7 million at the end of 2025 [8] - General and administrative expenses were reduced by $2.3 million in the first nine months of 2025 compared to the same period in 2024 [8] 2026 Anticipated Milestones - The company plans to conduct a Phase I study for CLD-401 targeting non-small cell lung cancer, triple-negative breast cancer, and head and neck cancer, with proof-of-concept data expected early in the trial [4][9] - Calidi aims to present data demonstrating the versatility of the RedTail platform for delivering tumor-localized BiTEs alongside T-cell amplifiers, addressing previous efficacy challenges in solid tumors [4][9] - The company is exploring new payloads for inflammatory and immune diseases, targeting other cell types through envelope engineering [4][9]